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Identifying pathways for cardiacmuscle creation is a paramount objective of cardiac stem cell biology. In this
issue of Cell Stem Cell, Shimoji and colleagues (2010) report the unforeseen ability of granulocyte colony-
stimulating factor (G-CSF) to drive cardiopoiesis in mouse, primate, and human pluripotent cells.Cardiovascular disease accounts for
more than a third of mortality in high-
income countries, the commonest form
being ischemic heart damage (myocardial
infarction) resulting from obstructed coro-
nary arteries. Cardiomyocyte death with-
out equivalent regeneration also is typical
of cardiomyopathies. Rescuing cardiac
muscle cell number is thus opportune
as one means to rescue the heart’s
performance as a biomechanical pump.
A priori approaches include preventing
apoptosis, stimulating survival pathways,
activating endogenous progenitors within
the heart (which, unassisted, are insuffi-
cient to restore the organ), and cell graft-
ing. More than 20 clinical trials of cell ther-
apy for heart repair have been reported
worldwide, chiefly with bone marrow
cells, whose benefits are better explained
by blood vessel formation and secreted
factors than by the transdifferentiation
once envisioned (Segers and Lee, 2008).
In contrast, the capacity to generate new
cardiac muscle is unquestionable for
embryonic stem cells (ESCs), induced
pluripotent stem cells (iPSCs), and pro-
genitor/stem cells from the heart itself.
Nevertheless, problems remain: if cardio-
poiesis is to be more than a rare unguided
event, there exists a compelling need to
pinpoint the signals and networks that
drive the necessary cardiac lineage deci-
sions or expansion of committed or differ-
entiated cells. This task is made more
complex by the varying and even dichoto-
mous roles factors play at different
developmental stages in vivo and in differ-
entiating ESCs, such as Wnts and bone
morphogenetic proteins that can alterna-
tively induce or repress cardiopoieisis
(Olson and Schneider, 2003; Yuasa
et al., 2005).
Building upon the previously reported
ability of Noggin, a bone morphogenetic
protein inhibitor, to stimulate cardiac myo-188 Cell Stem Cell 6, March 5, 2010 ª2010 Egenesis in differentiating ESCs (Yuasa
et al., 2005), Shimoji and colleagues iden-
tified the G-CSF receptor, gcsfr3, as
a Noggin-induced gene that is enriched
in developing mouse myocardium and
tested its utility as a potential target to
stimulate cardiopoiesis (Shimoji et al.,
2010). Expression of the G-CSF receptor
and its ligand was enriched in embryonic
cardiac myocytes at E9.5, peaking at
E10.5 and E12.5, respectively. Intra-
uterine administration of G-CSF on E9
increased cardiomyocyte proliferation.
Strikingly, a single dose of G-CSF at E9
conferred a persistently enlarged trabec-
ular layer and increased thickness of the
compact layer in late gestation and
neonatal hearts. This effect was abro-
gated in gcsfr3/ mice, which displayed
decreased proliferation of cardiomyo-
cytes during development, a thin-walled
hypoplastic heart, and 50% intrauterine
mortality. The effect on cycling in culture
was marked with cardiomyocytes isolated
at E9.5, minimal in cardiomyocytes from
E12.5 embryos, and unseen in those
from neonates.
Next, it was postulated that the G-CSF
receptor could be exploited in ESC-
derived cardiomyocytes. Indeed, G-CSF
increased the incidence of beating
mouse embryoid bodies 5-fold. The
normal upregulation of cardiac markers
was abrogated by neutralizing antibodies
to G-CSF. G-CSF did not alter the
downregulation of Brachyury/T, a key
marker of primitive mesoderm, or the
initial appearance of Nkx2.5, the cardio-
genic homeodomain transcription factor.
Rather, G-CSF specifically increased later
levels of Nkx2.5, suggesting a mitogenic
effect on committed progenitors rather
than an inductive one, an inference
substantiated by the incorporation of
BrdU by cells expressing the cardiogenic
transcription factor Mef2c. Remarkably,lsevier Inc.as the net result, most cells in G-CSF-
treated cultures expressed the cardiac
proteins examined.
Lastly, the authors tested the impact of
G-CSF on cardiomyogenesis in mar-
moset ESCs and human iPSCs. In both
cases, G-CSF increased the percentage
of beating embryoid bodies, upregulating
cardiac transcription factors and markers
of later cardiac differentiation (e.g.,
NKX2.5, TBX5, MYL2, MYH6, and NPPA
in hiPSCs).
In summary, the authors report a novel
mitogenic role for G-CSF in cardiac
lineage-committed cells, with potential
importance for generating nascent cardi-
omyocytes efficiently from ESCs, iPSCs
and, conceivably, heart-derived cardiac
progenitor cells. Toward these ends—
not only for therapeutic grafting but also
other applications requiring human heart
muscle, like toxicology screens, disease
models, and drug discovery—it will be
important to learn how G-CSF affects
specific cardiomyocyte subpopulations
(atrial, ventricular, conduction system)
and to determine its impact on biophys-
ical and pharmacological maturation.
G-CSF signaling has been investigated
chiefly in the hematopoietic system and
much remains to be learned in its role as
a cardiopoietin. Activation of G-CSFR
triggers multiple pathways involving JAK/
STAT, Ras/Mek/Erk, Src-related kinases,
Akt, and SOCS3 (Panopoulos and Wato-
wich, 2008). In the current study, G-CSF
and JAK2/STAT3 drove proliferation of
cardiomyocytes in embryoid bodies
and embryonic hearts, whereas G-CSF
and JAK/STAT promoted cardiomyocyte
survival, not proliferation, in adult mice
after infarction (Harada et al., 2005),
differences presumably reflecting age or
pathobiological context.
Human trials of G-CSF for heart repair
have already been undertaken, facilitated
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marrow stem cell transplantation. Two
broadly different perspectives are recog-
nizable, focused on cardiac myocytes,
as above, or more typically on bone
marrow-derived cells’ mobilization and
homing to injured hearts. Alone, G-CSF
impairs homing of bone marrow cells to
the heart, perhaps by inhibiting the migra-
tory response to SDF-1; by contrast,
G-CSF plus a CD26/dipeptidylpeptidase
IV inhibitor that elevates SDF1 levels
improved these cells’ recruitment to the
heart, augmenting vascularization, pump
function, and survival (Zaruba et al.,
2009). Cardiac-resident progenitor cells
are a third potential target, as indicated
by the fact that G-CSF may enhance the
number of cardiac Sca-1+ cells (Brunner
et al., 2008; cf. Harada et al., 2005). Is
G-CSFR functionally coupled in the
endogenous cardiac progenitor/stem
cells resident in adult human hearts? Are
salutary effects of G-CSF on the adult
heart mediated in part by these cells?
Might G-CSF be used to drive cardiopoie-
sis by adult cardiac progenitor cells, in
culture or in situ?
Optimization of any potential cardio-
poietin must take into account the effects
on proliferation as well as lineage
commitment. Proliferation can occur in
embryonic cardiomyocytes (Olson and
Schneider, 2003), and Shimoji et al.(2010) localized the proliferation evoked
by G-CSF to Mef2+ cells, Nkx2.5+ cells,
and a-actinin+ cells. However, suscepti-
bility to G-CSF was largely lost by E12.5.
It remains to be learned whether other
hypoplastic cardiac phenotypes impinge
on this axis, e.g., through precocious
differentiation, whether cardiac progeni-
tors from both heart fields require
G-CSF, and whether the effect of G-CSF
is entirely myocyte autonomous.
The unexpected cardiac-lethal pheno-
type of gcsfr3/ mice differs from the
original report of this knockout line, which
had no premature lethality and was said to
develop normally (Liu et al., 1996). This
inconsistency might be explained by the
differing genetic background (ultimately
backbred to C57Bl/6), but leads to the
more general consideration, how many
other essential cardiopoietins have been
overlooked in ostensibly conclusive
models? How might heart-forming factors
best be identified in the future? Comple-
mentary, higher-throughput approaches
to detect novel cardiopoietins have begun
to include robotic screens in stem cells
and other systems (Sadek et al., 2008).
Along with other ‘‘high-bandwidth’’ ap-
proaches like saturation mutagenesis,
these experimental platforms hold the
promise of defining workable triggers for
cardiac muscle creation, beyond the
insights obtainable in stem cells or modelCell Stem Ceorganisms manipulating just one factor or
pathway at a time, on an artisanal scale.REFERENCES
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In a recent paper inNature, Vierbuchen et al. (2010) show that fibroblasts can be directly converted into func-
tional neurons by defined factors. This finding sheds new light on the biology underlying cell-fate restrictions
and might offer a new avenue for studying neurological diseases.The finding that differentiated somatic
cells such as fibroblasts can be reprog-
rammed into induced pluripotent stemcells (iPSCs) by four (or even fewer)
transcription factors (TFs) revolutionized
the understanding of cellular plasticityand provided a novel tool to study devel-
opmental processes and mechanisms
of human disease (Takahashi et al.,ll 6, March 5, 2010 ª2010 Elsevier Inc. 189
